ART446 / Arum Therap - LARVOL DELTA

Pre-clinical evaluation of small molecule CHK2 inhibitor, ART446, pre-IND candidate that enhances the olaparib and irinotecan (AACR 2024) - "The pre-IND candidate ART446 exhibits promising potential in enhancing the therapeutic effects of Olaparib and Irinotecan. These findings provide a robust foundation for further clinical development, offering a strategic approach to overcome resistance in cancer treatment."

Preclinical • Breast Cancer • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Gastrointestinal Cancer • Oncology • Triple Negative Breast Cancer • BRCA1

Dual Disruption of DNA Repair by a Novel CHK2 Inhibitor, ART-446, and Olaparib is a Promising Strategy for Triple-Negative Breast Cancer Therapy. (PubMed, Biomol Ther (Seoul)) - "These findings underscore the potential of ART-446 to exploit DNA repair deficiencies and overcome resistance mechanisms associated with PARP inhibitors. By addressing the limitations of current treatments and expanding the utility of PARP inhibitors, ART-446 represents a promising candidate for DDR-targeted therapies, offering a novel approach to improve the outcomes of patients with TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • DRD